为您找到相关结果约35个

你是不是要搜索 期刊Tecentriq 点击跳转

CLINICAL PHARMACOLOGY ASSESSMENTS OF TECENTRIQ IMMUNOGENICITY.

Promising Survival Rates with Tecentriq in early TNBC

APPLE Congress 2019: Promising Data on Tecentriq in hepatocellular Carcinoma

Triple-negative Breast Cancer (TNBC): Neoadjuvant Benefits of Tecentriq (R) increases the pCR-Rate

Guideline-Update: Tecentriq and Bevacizumab as the new Standard for Patients with HCC

Atezolizumab (Tecentriq (R)): Activity, indication and modality of use in advanced or metastatic urinary

De-glycosylated membrane PD-L1 in tumor tissues as a biomarker for responsiveness to atezolizumab (Tecentriq

advanced Lung- and triple-negative Breast Cancer Promising phase III Data on Combination Therapies with Tecentriq

33rd German Cancer Congress Tecentriq shows a long Response and a median Overall Survival of 15.9 Months

EQ-5D UTILITY ESTIMATES FROM THE IMPOWER 133 TRIAL OF TECENTRIQ plus CARBOPLATIN plus ETOPOSIDE VS.

In vitro and in vivo studies of plant-produced Atezolizumab as a potential immunotherapeutic antibody

Atezolizumab as the First Systemic Therapy Approved for Alveolar Soft Part Sarcoma

Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC

Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology

Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer

为您找到相关结果约35个

共35条页码: 1/3页15条/页